Navigation Links
Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan

* New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone

EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results from a new study have shown patients taking two Novartis cardiovascular medicines -- the recently U.S.-approved drug Tekturna(R) (aliskiren) and the leading therapy Diovan(R) (valsartan) -- experienced greater reductions in blood pressure levels than those using either agent alone.

The study also found more patients receiving both Tekturna, which received U.S. approval in March and represents the first type of new high blood pressure medicine in a decade, and Diovan reached their treatment goal compared to either drug alone (ACC presentation #405).

Data from this trial involving 1,800 patients -- the first large-scale study to assess the potential benefits of combining these medicines -- were presented for the first time at the of Cardiology 56th Scientific Session in New Orleans.

Half of the patients in the eight-week trial taking both Tekturna and Diovan saw a reduction in blood pressure to the target of 140/90 mmHg (systolic/diastolic pressure), higher levels than seen in patients taking either of the medicines alone.

Tekturna and Diovan work in different ways to target the renin angiotensin system, one of the body's key regulators of blood pressure. Tekturna targets renin, an enzyme responsible for triggering a process that can lead to high blood pressure. Diovan, an angiotensin receptor blocker (ARB) and one of the world's most-prescribed cardiovascular medicines, works later in this system by blocking the action of angiotensin II, which causes narrowing of blood vessels.

"These study results are exciting because they suggest the value of different mechanisms of action when Tekturna and Diovan are used together," said Suzanne Oparil, MD, Director of the Vascular B
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, April 16, 2012 Pharmatek Laboratories, Inc., ... supporting the pharmaceutical industry, announced that it has ... a Qualicaps® FS3 Automated Liquid Filling and Banding ... Pharmatek,s manufacturing capabilities increases overall efficiency at the ...
... 16, 2012 ConvaTec Healthcare today announced that it will report ... CEO and George Kegler, CFO will host an analyst and investor ... To participate in the conference call within the U.S. and Canada, ... internationally, dial (708) 290-1340. The conference ID is ...
Cached Medicine Technology:Pharmatek Increases Liquid Filled Capsule Capacity 2Pharmatek Increases Liquid Filled Capsule Capacity 3
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... the potential to ward off depression among retirees, particularly ... online in The Journals of Gerontology, Series ... the article " Internet Use and Depression Among Retired ... ," the authors report that Internet use reduced the ... their study sample. , Late-life depression affects between ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... in heart rate patterns provide information on how the ... long considered heart rate patterns to be important indicators ... as in labor and delivery. Now a new study ... predict the rate at which children develop through their ...
... November 15, 2007, Washington, DCEnsuring that everyone in the ... is not enough to drive the kind of reform ... released today by the Commonwealth Fund Commission on a ... for all, changing the way doctors and other health ...
... doctors for some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay ... whether to allow certain drugs to be sold by ... officials listened to arguments for and against the proposal ... , But at the day,s end, the FDA officials ...
... a favourable clinical outcome in women with ovarian carcinoma, ... research published this week in the online open access ... family of peptide hormones, and the receptor GPR54 have ... tumours. In this study, researchers have shown that kisspeptin ...
... Nov. 14 The following is a,statement from ... Health,(TFAH):, "Trust for America,s Health (TFAH) urges ... Health and Human Services, Education and,Related Agencies Appropriations ... vital programs that:, -- Assist states, territories, ...
... Escalon Medical Corp.,(Nasdaq: ESMC ) today announced ... For the first quarter of fiscal 2008, the ... the $7,168,160, reported in the prior,year period. This decrease ... and Vascular business units, which decreased 3% and 2%,respectively, ...
Cached Medicine News:Health News:Fetal heart rate yields clues to children's later development 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 2Health News:Commonwealth Fund Commission issues reform recommendations for next president 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Predicting the future in ovarian cancer 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... an open platform for clinical diagnostic applications. The ... of 75, 100, 150 and 200 cm ... laboratory space and throughput requirements. Tecan will focus ... new applications and to evolve the quality, safety ...
... For maximum productivity, and proven reliability, ... compact, fully automatic cell washing and ... fast 80-second wash cycle for stat ... controls, and standardized, reproducible procedures. High ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
Medicine Products: